Výsledky vyhledávání - "Maricla, Galetti"

Akademický článek

Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models

Autor: Silvia La Monica, Federica Vacondio, Kamal Eltayeb, Alessio Lodola, Francesco Volta, Martina Viglioli, Francesca Ferlenghi, Francesca Galvani, Maricla Galetti, Mara Bonelli, Claudia Fumarola, Andrea Cavazzoni, Lisa Flammini, Michela Verzè, Roberta Minari, Pier Giorgio Petronini, Marcello Tiseo, Marco Mor, Roberta Alfieri

Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)

Abstract The EGFR tyrosine kinase inhibitor osimertinib has been approved for the first-line treatment of EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) patients. Despite its efficacy, patients develop resistance. Mechanisms of resistance are hetero

Externí odkaz: https://doaj.org/article/8eb304e906fc460c924afda0b45c67be

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models

Autor: Pietro Delcanale, Manuela Maria Alampi, Andrea Mussini, Claudia Fumarola, Maricla Galetti, Pier Giorgio Petronini, Cristiano Viappiani, Stefano Bruno, Stefania Abbruzzetti

Publikováno v: Pharmaceutics, Vol 15, Iss 12, p 2776 (2023)

Photo-immunotherapy uses antibodies conjugated to photosensitizers to produce nanostructured constructs endowed with targeting properties and photo-inactivation capabilities towards tumor cells. The superficial receptor density on cancer cells is con

Externí odkaz: https://doaj.org/article/02b747e7715547e288a5ddc8edac90e4

Zobrazit plný text záznamu

Akademický článek

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

Autor: Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, Mara Bonelli, Andrea Cavazzoni, Maricla Galetti, Rita Terenziani, Kamal Eltayeb, Francesco Volta, Silvia Zoppi, Patrizia Bertolini, Gabriele Missale, Roberta Alfieri, Pier Giorgio Petronini

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with a poor prognosis and limited treatment options. Considering that alterations of the CDK4/6-cyclin D-Rb pathway occur frequently in HCC, we tested the efficacy of two CDK4/6

Externí odkaz: https://doaj.org/article/0992581364ca4a6f8a9441a26fe2edb3

Zobrazit plný text záznamu

Akademický článek

Subchronic exposure to titanium dioxide nanoparticles modifies cardiac structure and performance in spontaneously hypertensive rats

Publikováno v: Particle and Fibre Toxicology, Vol 16, Iss 1, Pp 1-18 (2019)

Abstract Background Non-communicable diseases, intended as the results of a combination of inherited, environmental and biological factors, kill 40 million people each year, equivalent to roughly 70% of all premature deaths globally. The possibility

Externí odkaz: https://doaj.org/article/ffd873d7d1bf46f0840221599f35a53f

Zobrazit plný text záznamu

Akademický článek

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Autor: Silvia La Monica, Roberta Minari, Daniele Cretella, Lisa Flammini, Claudia Fumarola, Mara Bonelli, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Denise Madeddu, Angela Falco, Costanza Annamaria Lagrasta, Anna Squadrilli, Elisabetta Barocelli, Alessandro Romanel, Federico Quaini, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-12 (2019)

Abstract Background The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment

Externí odkaz: https://doaj.org/article/0332689cda2e4440a52ebd48a300166b

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines

Autor: Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, Mara A. Bonelli, Daniele Cretella, Roberta Alfieri, Andrea Cavazzoni, Maricla Galetti, Patrizia Bertolini, Gabriele Missale, Pier Giorgio Petronini

Publikováno v: Frontiers in Oncology, Vol 10 (2020)

Advanced hepatocarcinoma (HCC) is an aggressive malignancy with poor prognosis and limited treatment options. Alterations of the cyclin D-CDK4/6-Rb pathway occur frequently in HCC, providing the rationale for its targeting at least in a molecular sub

Externí odkaz: https://doaj.org/article/8418daaeacfe4bb8a19f8913f2720e0d

Zobrazit plný text záznamu

Interaction between occupational radon exposure and tobacco smoke: a systematic review

Autor: Giuseppina Folesani, Maricla Galetti, Silvia Ranzieri, Pier Giorgio Petronini, Silvia La Monica, Massimo Corradi, Delia Cavallo

Publikováno v: Expert Review of Respiratory Medicine. 16:787-800

The risk of lung cancer from radon exposure was small compared to tobacco smoking (BEIR VI), but the relationship between these two carcinogenic agents has yet to be quantitatively estimated. The objective of this systematic review was to evaluate th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66ab024cff6bd1d064babfd267afd5bd
https://doi.org/10.1080/17476348.2022.2108795

Zobrazit plný text záznamu

Akademický článek

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines

Autor: Claudia Fumarola, Nicole Bozza, Riccardo Castelli, Francesca Ferlenghi, Giuseppe Marseglia, Alessio Lodola, Mara Bonelli, Silvia La Monica, Daniele Cretella, Roberta Alfieri, Roberta Minari, Maricla Galetti, Marcello Tiseo, Andrea Ardizzoni, Marco Mor, Pier Giorgio Petronini

Publikováno v: Frontiers in Oncology, Vol 9 (2019)

Fibroblast Growth Factor Receptors (FGFR1–4) have a critical role in the progression of several human cancers, including Squamous Non-Small-Cell Lung Cancer (SQCLC). Both non-selective and selective reversible FGFR inhibitors are under clinical inv

Externí odkaz: https://doaj.org/article/8bf71d887cd94dd983495c34f971bea4

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání